Clinical trial
A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels
NCT06580106 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels
- Lead sponsor
- Wake Forest University Health Sciences
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- April 9, 2025
- Completion date
- January 31, 2030
- Enrollment
- 50 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.